Beacon

Multi-payload ADCs are rapidly emerging as one of the most discussed areas of ADC innovation. But are they the next breakthrough in ADC innovation, or is the market getting ahead of the data? Join us on 29 September for an exclusive first look at our Multi-Payload ADC Landscape Report and gain early access to proprietary market intelligence before key clinical data emerges. We'll explore: 🔹Pipeline growth and competitive activity 🔹Target, payload and linker strategies shaping the landscape 🔹Key clinical development trends and upcoming catalysts 🔹What this means for ADC development, partnering and portfolio strategy Plus, hear expert perspectives during a fireside chat featuring leading voices from across the ADC field. 📅 29 September | 4PM BST | 11AM ET | 8AM PT Register now to secure your spot 👉 https://lnkd.in/e-WCAZwR #ADC #AntibodyDrugConjugates #Oncology #Biotech #DrugDevelopment #Pharma #MultiPayloadADCs #ADCs

Hot take: AI isn't the competitive advantage. The data behind it is. Most organizations will have access to powerful AI tools. What they won't have is the same depth, quality, and scientific rigor in their data. AI can only work with what it's given. If the underlying data is incomplete, inconsistent, or lacking context, the output will reflect that. But when AI is built on a strong scientific foundation, that's where real value starts to emerge. The conversation around AI often focuses on the tools. But over time, the real differentiator will be the quality of the data powering them. That's why we're focused on building high-quality, scientifically curated data at Beacon. Book a demo to see how Beacon's AI-ready data helps teams uncover insights faster and make more confident decisions: https://ter.li/w32twf6x

❌ Generic databases and AI can create costly blind spots for your R&D into cardiovascular, renal and metabolic diseases. 💡 Beacon CVRM helps you identify emerging opportunities, benchmark competitors and understand where true differentiation still exists.

❌ Crowded targets. Limited visibility. Bigger risks. 💡 Beacon CVRM brings clarity to complex markets, helping you evaluate competition and uncover whitespace with confidence.

As competition intensifies across cardiovascular, renal and metabolic disease, identifying the best strategic opportunities is increasingly difficult. Discover how Beacon CVRM uncovers whitespace, benchmarks competitors and accelerates strategic analysis with comprehensive, structured data.

🧠 How close are we to truly predictive, accessible biomarkers in Alzheimer’s disease? Join us with Circular Genomics for an expert-led conversation with Nikolas Mellios, MD, PhD and Henrik Zetterberg, MD, PhD as we explore the next wave of innovation in brain‑derived circular RNA (circRNA). In this session, we’ll unpack: • The biological significance and stability of brain‑derived circRNA, and how this enables blood‑based detection • The latest clinical validation data on circRNA performance in identifying Alzheimer’s disease and predicting progression • The future potential of circRNA biomarkers, including emerging research applications For researchers, clinical teams, and CI leaders, this is a key opportunity to understand how circRNA biomarkers could reshape the Alzheimer’s landscape. Secure your spot 👉 https://lnkd.in/e55a8i7U #circRNA #AlzheimersResearch #Biomarkers #Neurodegeneration #PrecisionMedicine #CNS #Biotech